MedPath

Responsive Nature-Driven Imagery to Reduce Delirium After Cardiac Surgery

Not Applicable
Not yet recruiting
Conditions
Agitation
Cardiac Surgery Recovery
Delirium - Postoperative
Anxiety
Registration Number
NCT07051096
Lead Sponsor
University of British Columbia
Brief Summary

The goal of this clinical trial is to learn if a novel device (MindfulGarden) is beneficial in a population of patients undergoing cardiac surgery. The main questions it aims to answer are:

Is a novel device (MindfulGarden) that uses responsive nature-driven imagery feasible in patients undergoing cardiac surgery? Will use of this device reduce the use of psychotropic medications, improve recovery experience, and improve delirium?

Participants will receive routine post-operative management and standard delirium reduction measures. They will be randomized into two groups where one receives the novel device (MindfulGarden) and the other does not.

Detailed Description

Hypotheses:

This study will explore: (1) the feasibility of using Mindful Garden-a novel, nature-based digital therapeutic device offering responsive imagery and sound with biofeedback-in patients undergoing cardiac surgery; and (2) whether its use reduces psychotropic medication use, agitation, anxiety, and both the incidence and duration of postoperative delirium.

Rationale:

Delirium is a frequent, serious complication after cardiac surgery, leading to prolonged hospital stays, increased costs, and higher mortality rates. Although medications are often used to manage delirium-related behavior, they can lead to over-sedation and do not reliably prevent or treat delirium. There is an urgent need for safe, effective, non-pharmacological interventions in high-risk groups. Mindful Garden offers a screen-based display of dynamic nature scenes with interactive elements that respond to physiological cues. In prior ICU settings, brief exposure to Mindful Garden reduced agitation and the need for unscheduled medications. However, its effectiveness in preventing or managing delirium specifically in cardiac surgical patients remains unexplored.

Objectives:

The primary goals are to evaluate the feasibility of implementing Mindful Garden (in terms of recruitment, adherence, data completeness), its usage patterns, and patient satisfaction. Secondary aims include assessing the device's impact on delirium incidence and severity, need for psychotropic medications, agitation levels, anxiety, postoperative recovery, and length of hospital stay.

Participants:

This pilot randomized controlled trial will enroll 60 adult patients (aged ≥18 years) undergoing open-heart surgery at St. Paul's Hospital in Vancouver, Canada. Each arm will include 30 patients. Participants must have at least one risk factor for delirium, including being aged 64 or older, a history of delirium, stroke or TIA, cognitive impairment, or depression. Individuals with severe pre-existing cognitive impairments will be excluded.

Intervention:

Participants will be randomized 1:1 to either the Mindful Garden intervention or standard care. Due to the nature of the intervention, blinding is not feasible. In the intervention group, the Mindful Garden device will be made available for up to 7 days postoperatively or until discharge. All participants will receive standard post-operative care, including routine non-drug delirium prevention measures.

Outcomes:

Primary feasibility outcomes include recruitment success, adherence to study protocol, and participant satisfaction. Secondary clinical outcomes involve:

* Frequency of unscheduled psychotropic medication use

* Incidence and severity of delirium (measured via the Intensive Care Delirium Screening Checklist and Confusion Assessment Method)

* Agitation (Richmond Agitation Sedation Scale)

* Anxiety (State Trait Anxiety Inventory)

* Recovery quality (QoR-15 score)

* Presence of Hallucinations (PSYRATS)

* Hospital length of stay

Anticipated Impact:

This pilot trial will assess whether integrating the Mindful Garden device into post-cardiac surgery care is practical and beneficial. Results will inform a larger trial and may support broader implementation of non-pharmacological digital therapeutics to enhance recovery, reduce delirium, and minimize reliance on psychoactive drugs in surgical settings.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Planned open-heart cardiac surgery (e.g. coronary artery bypass grafting, valve replacement surgery);
  • Able to understand study procedures and provide informed consent in English;
  • At least one delirium risk factor: 1) Age less than 65yrs; 2) History of delirium; 3) History of stroke/TIA; 4) Known cognitive impairment; 5) Depression requiring medication.
Exclusion Criteria
  • Severe pre-existing cognitive impairment (Montreal Cognitive Assessment [MOCA6]<10)
  • Uncorrected visual impairment;
  • Significant impairment from psychiatric disease;
  • Enrolment in another clinical trial which may interfere with the study outcome measures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Adherence to Protocol RateDay 30 post surgery
Recruitment RateDay 0
Time Spent with DeviceDay 7 post surgery or discharge, whichever comes first
Patient Satisfaction and Perceived BenefitsDay 7 post surgery or discharge, whichever comes first

Using a Likert Scale in a patient satisfaction questionnaire. The Likert Scale uses 1 as Strongly Disagree and 5 as Strongly Agree.

Secondary Outcome Measures
NameTimeMethod
Number of Unscheduled Psychoactive Medications or IV InfusionsDay 7 post surgery or discharge, whichever comes first

Examples of medications are haloperidol, loxapine, and dexmedetomidine

Length of CSICU and hospital stays (days)Day 30 or day of discharge, whichever comes first
Patient reported Quality of RecoveryDay 0, 3, 30 post surgery

Measured using Quality of Recovery (QoR-15). Patients score items on a 1 to 5 scale with 1 being Not at All and 5 being Extremely. These scores are totalled where 15-30 indicates Poor Quality of Recovery, 31-50 indicates Moderate Quality of Recovery, and 51-75 indicates Good Quality of Recovery.

Incidence and Severity (days) of DeliriumTwice daily until Day 7 post surgery or discharge, whichever comes first

Measured by the Intensive Care Delirium Screening Checklist in the CSICU and the Confusion Assessment Method after discharge to the ward.

Agitation in CSICUEvery 4 hours while admitted to CSICU

Measured using the Richmond Agitation Sedation Scale:

Positive scores (+1 to +4): Indicate increasing agitation or restlessness. Negative scores (-1 to -5): Indicate increasing levels of sedation or unconsciousness.

A score of 0: represents the desired state of alertness and calmness

Patient reported outcomes of anxietyDay 0, 3, 30 post surgery

Patient reported outcomes of anxiety will be measured using the State Trait Anxiety Inventory. The State Trait Anxiety Inventory consists of 40 items in total. 20 items for State Anxiety (S-Anxiety) range 20-80 and 20 items for Trait Anxiety (T-Anxiety) range 20-80.

Presence of hallucinations and delusionsDay 3 post surgery

Measured using the Psychotic Symptom Rating Scales (PSYRATS). PSYRATS has 2 subscales: Auditory Hallucinations (AH) and Delusions (D). AH has 11 items each scored 0-4 with a sum of 0 indicating no symptoms and a sum of 44 indicating most severe symptoms. D has 6 items each scored 0-4 with a sum of 0 indicating no symptoms and a sum of 24 indicating most severe symptoms.

Trial Locations

Locations (1)

St. Paul's Hospital

🇨🇦

Vancouver, British Columbia, Canada

St. Paul's Hospital
🇨🇦Vancouver, British Columbia, Canada
Alana Flexman, MD
Contact
604-682-2344
aflexman@providencehealth.bc.ca
© Copyright 2025. All Rights Reserved by MedPath